{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:00:13Z","timestamp":1770523213687,"version":"3.49.0"},"reference-count":75,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T00:00:00Z","timestamp":1421712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:p>The B\u2010cell receptor pathway (BCR) is aberrantly activated in select B\u2010cell malignancies. This knowledge has allowed for the development of inhibitors of different crucial steps of this pathway. Bruton's tyrosine kinase (BTK) is a key component of BCR signaling and functions as an important regulator of multiple cell functions including differentiation, proliferation, and survival in various B\u2010cell malignancies. Ibrutinib is a potent, selective BTK inhibitor that has shown significant activity in specific subtypes of B\u2010cell non\u2010Hodgkin's lymphomas (NHLs). Given the high response rates, tolerability, and acceptable toxicities, ibrutinib was recently approved by the US Food and Drug Administration (FDA) for the treatment of patients with relapsed mantle cell lymphoma and chronic lymphocytic leukemia. It is also currently being evaluated in combination with chemotherapy and as frontline therapy in B\u2010cell NHL. This review summarizes the preclinical and clinical development of ibrutinib in the treatment of B\u2010cell NHL.<\/jats:p>","DOI":"10.1002\/cpt.65","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T15:47:37Z","timestamp":1429544857000},"page":"469-477","source":"Crossref","is-referenced-by-count":27,"title":["Bruton's tyrosine kinase inhibitors in B\u2010cell non\u2010Hodgkin's lymphomas"],"prefix":"10.1111","volume":"97","author":[{"given":"L","family":"Alinari","sequence":"first","affiliation":[{"name":"Department of Hematology Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center Columbus Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Quinion","sequence":"additional","affiliation":[{"name":"Department of Hematology Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center Columbus Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KA","family":"Blum","sequence":"additional","affiliation":[{"name":"Department of Hematology Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center Columbus Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,1,20]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21166"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23615"},{"key":"e_1_2_11_3_1","first-page":"326","article-title":"Appropriate management of molecular subtypes of diffuse large B\u2010cell lymphoma","volume":"28","author":"Dunleavy K.","year":"2014","journal-title":"Oncology"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-565135"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.91"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-255067"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri955"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.04.008"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.22.10606"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1589"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-003921"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.72"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-100115"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11309"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-343434"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.09.006"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802885"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5250.822"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311985200"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.11.012"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3190"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8332901"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830241228"},{"key":"e_1_2_11_27_1","first-page":"574","article-title":"Expression of the X\u2010linked agammaglobulinemia gene, btk in B\u2010cell acute lymphoblastic leukemia","volume":"8","author":"Katz F.E.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61272"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-011-0019-7"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05883.x"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100095"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-475111"},{"key":"e_1_2_11_34_1","article-title":"The WHIM\u2010like CXCR4 somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","author":"Cao Y.","year":"2014","journal-title":"Leukemia"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1861"},{"key":"e_1_2_11_36_1","first-page":"1676","volume":"319","author":"Lenz G.","year":"2008","journal-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.62"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09671"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482125"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_2_11_48_1","article-title":"Functional characterization of BTK mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","author":"Cheng S.","year":"2014","journal-title":"Leukemia"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3435"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-230250"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07998.x"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_2_11_55_1","doi-asserted-by":"crossref","unstructured":"Blum K.A.et al.Poor overall survival of patients with ibrutinib\u2010resistant mantle cell lymphoma. ASH Annual Meeting Abstracts 3047(2014).","DOI":"10.1182\/blood.V124.21.3047.3047"},{"key":"e_1_2_11_56_1","doi-asserted-by":"crossref","unstructured":"Wilson W.H.et al.The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI\u201032765) has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B\u2010cell lymphoma (DLBCL): interim results of a multicenter open\u2010label phase 2 study. ASH Annual Meeting Abstracts 120 686(2012).","DOI":"10.1182\/blood.V120.21.686.686"},{"key":"e_1_2_11_57_1","doi-asserted-by":"crossref","unstructured":"Treon S.P.et al.A prospective multicenter study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom's macroglobulinemia. ASH Annual Meeting Abstracts 251(2013).","DOI":"10.1182\/blood.V122.21.251.251"},{"key":"e_1_2_11_58_1","doi-asserted-by":"crossref","unstructured":"Fowler N.H.et al.The Bruton's tyrosine kinase inhibitor ibrutinib (PCI\u201032765) is active and tolerated in relapsed follicular lymphoma. ASH Annual MeetingAbstracts 120 156(2012).","DOI":"10.1182\/blood.V120.21.156.156"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311846111"},{"key":"e_1_2_11_60_1","doi-asserted-by":"crossref","unstructured":"Sahakian E.et al.Combination of ACY1215 a selective histone deacetylase 6 (HDAC6) inhibitor with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib represents a novel therapeutic strategy in mantle cell lymphoma (MCL).ASH Annual Meeting Abstracts 120 1660(2012).","DOI":"10.1182\/blood.V120.21.1660.1660"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.05.024"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12206"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1422-5"},{"key":"e_1_2_11_64_1","article-title":"A phase 1\/1b study of combined rituximab, bendamustine, and ibrutinib in patients with previously untreated and relapsed\/refractory non\u2010Hodgkin's lymphoma","author":"Maddocks K.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70311-0"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.481"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38047"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.040840"},{"key":"e_1_2_11_69_1","first-page":"1224","article-title":"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha\u2010cyano\u2010beta\u2010hydroxy\u2010beta\u2010 methyl\u2010N\u2010(2,5\u2010dibromophenyl)propenamide (LFM\u2010A13), a novel antileukemic agent targeting Bruton's tyrosine kinase","volume":"8","author":"Uckun F.M.","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_11_70_1","doi-asserted-by":"crossref","unstructured":"Gardner H.L.et al.ACP\u2010196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B\u2010cell non\u2010Hodgkin lymphoma. AACR Annual Meeting Abstract1744(2014).","DOI":"10.1158\/1538-7445.AM2014-1744"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203489"},{"key":"e_1_2_11_72_1","unstructured":"Eda H.et al.CC\u2010292 a novel Bruton's tyrosine kinase inhibitor alone and in combination with carfilzomib impacts bone resorption in multiple myeloma by blocking osteoclast sealing zone formation. EHA 2013 Congress Abstract S543 (2013)."},{"key":"e_1_2_11_73_1","doi-asserted-by":"crossref","unstructured":"Brown J.et al.Phase 1 Study of single agent CC\u2010292 a highly selective Bruton's tyrosine kinase (BTK) inhibitor in relapsed\/refractory chronic lymphocytic leukemia (CLL) and B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL). EHA 2013 Congress Abstract S520 (2013).","DOI":"10.1182\/blood.V122.21.1630.1630"},{"key":"e_1_2_11_74_1","volume-title":"A Phase I Study of the Oral Btk Inhibitor ONO\u20104059 in Patients With Relapsed\/Refractory B\u2010Cell Lymphoma","author":"Shah N.","year":"2013"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702654104"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.65","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:28:37Z","timestamp":1699363717000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,20]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/cpt.65"],"URL":"https:\/\/doi.org\/10.1002\/cpt.65","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,20]]}}}